# QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study

> **NCT07649473** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Colon Cancer
- Synchronous Liver Metastases

## Interventions

- **DRUG:** QL1706 (Iparomlimab/Tuvonralimab)

## Key facts

- **NCT ID:** NCT07649473
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2028-12-31
- **Final completion:** 2033-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07649473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07649473, "QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07649473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*